Head-to-head evidence
Clozapine vs Perseris
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Clozapine
Marketed by HLS Therapeutics Inc.
NCT00250575 · Phase 3 · completed
The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.
Next expected readout: April 2027 · NCT04580134 (registry estimate)
Perseris
Marketed by Indivior Pharmaceuticals, Inc.
NCT02109562 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 354 participants and a clinical primary endpoint measuring change in PANSS total score. The primary endpoint was met for both RBP-7000 doses: PANSS scores improved significantly more than with placebo.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Perseris's landscape